Research programme: genetically engineered paraxonase 1 protein complex - BioLineRxAlternative Names: BL 3050
Latest Information Update: 16 Jul 2016
At a glance
- Originator Yeda Research and Development Company Ltd
- Mechanism of Action Enzyme modulators; Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in Israel
- 28 Mar 2007 Preclinical trials in Atherosclerosis in Israel (unspecified route)